A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

Table 1

Treatment exposure and the incidence of bilateral treatment (safety set).

	Ranibizumab 0.5 mg; total; (𝑁=755)
Number of injections in the first-treated eye
Year 1	3306
Mean (SD)	4.4 (2.3)
Overall (24 months)	4711
Mean (SD)	6.2 (4.3)
Patients with bilateral treatment over 24 months, 𝑛 (%)	133 (17.6)
Patients with bilateral treatment within 28 days, 𝑛 (%)	87 (11.5)

Safety set was defined as all those patients who were treated with at least one dose of ranibizumab and who had at least one safety assessment after study entry and no protocol deviations that warranted exclusion.
The total number of injections is number of injections received since the start of the study in the specific eye.
Patients with bilateral treatment represent the patients who received treatment in both eyes.
SD: standard deviation.